-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GeVd7SkIyDVOciweo4lI1bG9LO/6I7OAxjX3QESkSstQfmYrVSPLkU6Y47CZEN7A ATpi/LXw5oeQhWhsYR8pDw== 0000950135-05-006069.txt : 20051028 0000950135-05-006069.hdr.sgml : 20051028 20051028163617 ACCESSION NUMBER: 0000950135-05-006069 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20051027 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20051028 DATE AS OF CHANGE: 20051028 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIACELL INC CENTRAL INDEX KEY: 0001114529 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 043244816 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51110 FILM NUMBER: 051163644 BUSINESS ADDRESS: STREET 1: 131 CLARENDON ST CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 6172664373 8-K 1 b57583vie8vk.htm VIACELL, INC. e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 27, 2005
VIACELL, INC.
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-51110   04-3244816
         
(State or other jurisdiction of
of incorporation or organization) 		  (Commission
File Number) 		  (I.R.S. Employer
Identification No.)
245 First Street, Cambridge, Massachusetts 02142
 
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code: (617) 914-3400
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

TABLE OF CONTENTS

Item 8.01 Other Events
Item 9.01 Financial Statements and Exhibits.
SIGNATURE
EX-99.1 Press release issued by ViaCell, Inc. on October 27, 2005

Table of Contents

Item 8.01 Other Events
ViaCell, Inc. (“ViaCell”) issued a press release on October 27, 2005 announcing that Viacell has entered into an agreement to settle pending litigation with CBR Systems, Inc. A copy of the press release dated October 27, 2005 is being filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.
99.1 — Press release issued by ViaCell dated October 27, 2005.

 

Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
    VIACELL, INC.
 
        
Date: October 27, 2005
  By:   /s/ Anne Marie Cook
 
       
 
      Name: Anne Marie Cook
Title: Senior Vice President, Legal and General Counsel

 

Table of Contents

EXHIBIT INDEX
The following exhibit is filed herewith:
     
Exhibit   Description
99.1
  Press release issued by ViaCell, Inc. (“ViaCell”) on October 27, 2005 announcing that Viacell has entered into an agreement to settle pending litigation with CBR Systems, Inc.

 

EX-99.1 2 b57583viexv99w1.htm EX-99.1 PRESS RELEASE ISSUED BY VIACELL, INC. ON OCTOBER 27, 2005 exv99w1
 

Exhibit 99.1
For More Information Contact:
Justine E. Koenigsberg
Senior Director, Corporate Communications
(617) 914-3494
FOR IMMEDIATE RELEASE
ViaCell Announces Settlement of Litigation with CBR
Cambridge, MA, October 27, 2005 ¯ ViaCell, Inc. (NASDAQ:VIAC) announced today that it has entered into an agreement to settle pending litigation with CBR Systems, Inc. The dispute related to certain marketing claims made by each company. Under the terms of the settlement agreement the companies have agreed to dismiss all outstanding claims and counter claims in the litigation. No financial payment will be made by either party. Other terms of the settlement were not disclosed.
Marc D. Beer, President and Chief Executive Officer of ViaCell, commented, “We are pleased with the outcome of this settlement.”
About ViaCell
ViaCell is a biotechnology company focused on enabling the widespread use of human cells as medicine. The Company is developing a pipeline of proprietary stem cell product candidates intended to address cancer, cardiac disease, and diabetes. CB001, its lead cord blood derived stem cell therapy product candidate, is being developed for hematopoietic stem cell transplantation in patients affected by a variety of cancers. In addition to its therapeutic development programs, ViaCell’s reproductive health business unit commercializes ViaCord®, a product that offers expecting families the option of preserving their baby’s umbilical cord blood. The Company is working to leverage its commercial infrastructure and product development capabilities by developing ViaCyte™, its investigational product intended to broaden reproductive choices for women through the cryopreservation of human unfertilized eggs. ViaCell is headquartered in Cambridge, Massachusetts with a processing and storage facility in Kentucky and additional research and development operations in Singapore.
ViaCell® and ViaCord® are registered trademarks and ViaCyte™ is a trademark of ViaCell, Inc.
###

 

-----END PRIVACY-ENHANCED MESSAGE-----